Lumasiran

Active substance

lumasiran

Holder

Alnylam Netherlands B.V.

Status

Closed

Indication

treatment of primary hyperoxaluria type 1 (PH1) in patients who have reached at least 37 weeks estimated gestational age (full‐term infant) at consent (or assent)

Public documents 

Approbation

Information for the patient

Informed consent

Last update

01/06/2023